A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Yutaka Tomioka

Project Researcher, Department for the Promotion of Medical Device Innovation, National Cancer Center Hospital East.
Chief Regulatory Scientist, ayumo Inc.
Chief Development Officer / Director, Atransen Technologies, Inc.
Senior Specialist, Premo Partners, Inc.

Ph.D. (Engineering). I began my career at the Pharmaceuticals and Medical Devices Agency (PMDA), where I worked in medical device review and reliability inspection (reliability standards compliance inspections and on-site GCP inspections for medical devices). My responsibilities included the approval review, consultation services, and reliability inspections for a wide range of medical devices, including novel medical devices. Drawing on my 10 years of experience at the regulatory authority, I moved to National Cancer Center Hospital East in July 2019 to support the development of medical devices originating in Japan. At National Cancer Center Hospital East, I supported medical device development led by both academic institutions and companies. I left my full-time position at National Cancer Center Hospital East at the end of 2025, and joined ayumo Inc. in January 2026 (current position), where I lead the regulatory affairs team.I also joined Atransen Technologies, Inc. in May 2026 (current position). I currently hold part-time positions at National Cancer Center Hospital East, Yokohama City University, and the National Defense Medical College, while also supporting a number of startups, pharmaceutical companies, medical device manufacturers, academic institutions, and small manufacturing workshops (machi-koba) in Ota Ward, Tokyo.

Daisuke Sugiyama

Hiroshima University, Translational Research Center, Professor

He obtained his PhD thesis at University of Tokyo. After working at several hospitals as a clinician, he has engaged in medical reserach at University Paris 6 (French Government Scholar), Dartmouth College (JSPS research fellow), Kyushu University and Hiroshima University. Based on the experiences working at ARO research core hospital and starting up bio-venture company, he supports and conducts both translational and clinical researches.

Jun Utsumi

CEO, TIR Research Consulting LLC.

JU graduated from the Graduate School of Veterinary Medicine, Hokkaido University. He holds DVM, D.Sc., MBA and has licenses of Professional Engineer (biotechnology), Radiation Protection Supervisor and Certified Scientist of Medical AI. He was engaged in research and clinical development at Toray Industries, Inc. and succeeded in commercializing the world's first opioid kappa agonist (received Awards from the Pharmaceutical Society of Japan and Okochi Memorial Foundation). After the business career, he served as a professor in Hokkaido University and Kyoto University, as well as an expert in Pharmaceuticals and Medical Devices Agency (PMDA) and a senior consultant for intellectual property at the Japan Agency for Medical Research and Development (AMED). Over 30 years of experience led him to establish a consulting company in 2018, he is also involved in medical DX support and won the Japan Open Innovation Award in 2023. He is part-time lecturers at the graduate schools of the University of Tokyo, Kyoto University, Tokyo Medical and Dental University, and the University of Tsukuba. He published “A Guide to Integrated Strategy in Drug Discovery” (Nanzando Co., 2015).

Tadashi Sameshima

I have been engaged in product development and business operations of medical devices and regenerative medicine products for 37 years at Terumo Corporation. I have experienced the development of medical devices such as extracorporeal circulatory and blood transfusion devices, as well as the development to commercialization of cellular products. In addition, I am able to provide specific advice on various stages of development based on my participation in joint research with universities, collaboration among companies, discussions with government agencies, and activities of industry associations.

Atsushi Shimada

Chief Technology Development Officer ・ Specially Appointed Professor, Tohoku University Drug Discovery Strategy Promotion Organization
AN Venture Partners, Venture Partner
Patent attorney

Atsushi Shimada is a Specially Appointed Professor and Chief Technology Development Officer (CTDO) at Tohoku University, where he leads initiatives to accelerate the commercialization of academic innovations and the creation of university spinout companies. He also serves as a Venture Partner to AN Venture Partners, a cross-border life sciences venture capital firm investing in innovative biotechnology companies. Prior to joining Tohoku University, Mr. Shimada held leadership positions in intellectual property, business development, and corporate strategy at Takeda Pharmaceutical Company and Bayer. He subsequently became a life sciences investor, supporting the formation, financing, and growth of early-stage biotechnology startups. Throughout his career, he has led numerous strategic licensing transactions, M&A projects, technology transfer initiatives, venture investments, and intellectual property strategies across a broad range of therapeutic areas. As a registered Japanese Patent Attorney, Mr. Shimada combines scientific expertise with extensive experience in intellectual property, venture capital, and pharmaceutical business development. He has worked closely with researchers, entrepreneurs, pharmaceutical companies, universities, and investors to translate cutting-edge scientific discoveries into successful commercial ventures. As a MEDISO Startup Support Mentor, Mr. Shimada provides practical guidance on startup formation, business strategy, intellectual property, licensing, fundraising, and global commercialization. Drawing on his unique perspective as both a technology commercialization executive and venture investor, he is committed to helping researchers and entrepreneurs build globally competitive life sciences startups and maximize the societal impact of their innovations.